Foltyn Wanda, Kos-Kudła Beata, Marek Bogdan, Kajdaniuk Dariusz, Głogowska-Szelag Joanna, Siemińska Lucyna, Strzelczyk Janusz, Borowska Małgorzata
Klinika Endokrynologii, Katedra Patofizjologii i Endokrynologii w Zabrzu, Slaska Akademia Medyczna, Katowice.
Endokrynol Pol. 2007 Mar-Apr;58(2):170-5.
Prolonged glucocorticoids administration is the most common cause of secondary osteoporosis. It is estimated that 30% to 50% of chronic glucocorticoids users experience vertebral or hip fractures. The highest bone loss (up to 30% in some studies) is observed in the first six months of treatment. Only a minority of patients who take chronic glucocorticoids receive optimal osteoporosis diagnosis, prevention, and/or treatment. The aim of this paper is to present the pathophysiology of glucocorticoid-induced osteoporosis, as well as some guidelines on diagnostic, preventive and therapeutic strategies for this disorder in an effort to promote the greater awareness of it.
长期使用糖皮质激素是继发性骨质疏松最常见的原因。据估计,30%至50%的慢性糖皮质激素使用者会发生椎体或髋部骨折。在治疗的前六个月观察到最高的骨质流失(在一些研究中高达30%)。仅有少数长期使用糖皮质激素的患者得到了最佳的骨质疏松症诊断、预防和/或治疗。本文旨在阐述糖皮质激素性骨质疏松的病理生理学,以及关于该疾病诊断、预防和治疗策略的一些指南,以提高人们对其的认识。